Johnson & Johnson (JNJ) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $240.10. It has a SharesGrow Score of 73/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of JNJ = $268.06 (+11.6% from the current price, the stock appears fairly valued). Analyst consensus target is JNJ = $229 (-4.7% upside).
Valuation: JNJ trades at a trailing Price-to-Earnings (P/E) of 21.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.5.
Financials: revenue is $94.2B, +5.6%/yr average growth. Net income is $26.8B, growing at +42.2%/yr. Net profit margin is 28.5% (strong). Gross margin is 72.8% (+3.5 pp trend).
Balance sheet: total debt is $47.9B against $81.5B equity (Debt-to-Equity (D/E) ratio 0.59, moderate). Current ratio is 1.03 (adequate). Debt-to-assets is 24.1%. Total assets: $199.2B.
Analyst outlook: 20 / 40 analysts rate JNJ as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 38/100 (Fail), Growth 83/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 100/100 (Pass), Future 38/100 (Fail), Income 85/100 (Pass).
